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Abstract
Background: Clinical data indicates that delivery of larger daily doses of radiation may improve the therapeutic
ratio for prostate cancer compared to conventional fractionation. A phase II study of stereotactic body radiotherapy
with real-time motion management and daily plan re-optimization for low to intermediate risk prostate cancer was
undertaken to evaluate this hypothesis. This report details the toxicity and quality of life following treatment.
Methods: From 2009 to 2013, 60 patients with T1–T2c prostate cancer with a Gleason score of 6 and PSA ≤ 15 or
Gleason score of 7 and PSA ≤ 10 were enrolled. Patients with nodal metastases, an American Urological Association
symptom score > 18, or gland size > 100 g were not eligible. Patients were treated to 37 Gy in 5 fractions. Early and
late genitourinary and gastrointestinal toxicity were graded based on NCI CTCAE v4.0 and quality of life was
assessed by the American Urological Association symptom score, International Index of Erectile Function, and
Expanded Prostate cancer Index Composite Short Form up to 36 months after treatment.
Results: After a median follow-up of 27.6 months, no grade 3 or greater genitourinary toxicity was observed. Four
patients (6.7%) reported a late grade 2 genitourinary toxicity. One patient (1.7%) reported a late grade 3 gastrointestinal
toxicity. Five patients (8.3%) developed a late grade 2 gastrointestinal toxicity. The median American Urological
Association symptom score increased from 4.5 prior to treatment to 11 while on treatment (p < 0.01), but was 5 at
36 months post-treatment (p = 0.65). Median International Index of Erectile Function scores decreased from 19 to 17
over the course of follow-up (p < 0.01). Only median scores within the Expanded Prostate Cancer Index Composite
Short Form sexual domain were significantly decreased at 36 months post-treatment (67.9 vs 45.2, p = 0.02). There was
no significant difference in median score within the urinary, bowel, or hormonal domains at 36 months of follow-up.
Conclusions: Stereotactic body radiotherapy for low to intermediate risk prostate cancer is well tolerated with limited
toxicity or decrease in quality of life. Longer follow-up is necessary to assess the efficacy of treatment.
Trial registration: Clinicaltrials.gov NCT00941915 Registered 17 June 2009.
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Background
Conventional treatment of localized prostate cancer with
radiation alone involves doses to 74 Gy or greater given
over 8 to 9 weeks. This regimen is based on four ran-
domized trials showing improved progression free sur-
vival compared to lower cumulative doses, however at
the cost of increased toxicity [1–4]. Given this concomi-
tant increase in toxicity with dose, as well as the expense
and inconvenience of protracted courses, alternative
treatment schemes have been investigated.
The relationship of cellular death to radiation dose for
rapidly dividing cells is dominated by a linear component,
represented by a large α/B ratio, such that changes in frac-
tion size have a small impact on efficacy. More slowly div-
iding cells, with a relatively small α/β are more sensitive to
changes in fraction size when delivered to equivalent total
doses. There is clinical data [5, 6] that suggests that pros-
tate cancer has a low α/β compared to surrounding nor-
mal tissues and therefore increasing daily radiation
fraction size will have a greater effect on the tumor and in-
crease the therapeutic ratio. Hypofractionation, or the de-
livery of fewer, larger fractions to a lower total dose, may
allow for increased tumor control and limit the toxicity
and practical disadvantages of dose escalation.
Stereotactic body radiation therapy (SBRT) allows for the
delivery of large radiation doses through incorporation of
coordinate systems and accounting for organ motion via
daily imaging. Previous reports have demonstrated the feasi-
bility of this technique and high rates of intermediate term
biochemical control for patients with low and intermediate
risk prostate cancer [7–12]. Here, we report the acute and
long-term toxicity of a phase II, multi-institutional study of
SBRT for low to intermediate risk prostate cancer.
Methods
Patients and eligibility criteria
Men over the age 40 with prostate adenocarcinoma with a
Gleason score ≤ 7, clinical stage T1–T2c, and PSA ≤
15 ng/ml if their Gleason score was ≤ 6 or PSA ≤ 10 ng/ml
if their Gleason score was seven were eligible for this
study. Other eligibility criteria included a pathological
diagnosis within 365 days of enrollment, history and phys-
ical exam including digital rectal exam within 8 weeks of
enrollment, and a Zubrod performance status of 0–1. Ex-
clusion criteria included node positive or metastatic dis-
ease, AUA score > 18, prostate size > 100 g, previous
surgery for prostate cancer, prior pelvic irradiation, or pre-
vious or concurrent androgen deprivation therapy.
Patients were recruited at three centers: Duke Univer-
sity Medical Center in Durham, NC, Coastal Carolina
Radiation Oncology in Wilmington, NC, and Walter
Reed National Military Medical Center in Bethesda, MD.
Institutional review board approval was obtained at each
center and all participants provided written informed
consent before registration.
Treatment planning
The clinical target volume (CTV) was the prostate as de-
termined by planning CT scan with 1 to 1.25 mm slice
thickness without contrast. All patients completed a blad-
der and rectal preparation protocol including 1 tablespoon
of milk of magnesia the evenings prior to simulation and
treatment and a Fleet’s enema with 16–24 oz of water 2–3
h before simulation and treatments. This was shown to
minimize intra-fraction motion based on analysis of the
first 15 treated patients. Based on this minimal motion,
planning based on fused CT/MRI image sets was allowed
after this time. The seminal vesicles were not included in
the CTV as the risk of this in patients with a combined
Gleason score of seven but primary Gleason score of three
has been shown to be 4% [13]. The planning target vol-
ume (PTV) was created by expanding the CTV by 5 mm
in all directions except by 3 mm posteriorly [9]. The total
dose was prescribed to cover ≥ 95% of the PTV via inten-
sity modulated radiotherapy (IMRT) with a minimum of
seven non-opposed fields or two arc rotational fields. For
IMRT, fluence mapping of each field was optimized via
minimizing a cost function combining PTV coverage and
OAR sparing followed by a leaf-motion optimization that
converts the fluence map in to a sliding window delivery.
And for rotational fields, a similar cost function was used
for the optimization, where gantry positions, MLC leaf po-
sitions and dose at each gantry position were optimized.
The maximum doses to the rectum and bladder were 105
and 110% of the prescription dose, respectively. Fifty percent
of the rectum was limited to ≤ 24 Gy and up to 40 cc of
bladder could receive > 24 Gy. The maximum doses to the
penile bulb and femoral heads were 100 and 81%, respect-
ively. Isodose curves at mid-prostate for a representative pa-
tient are shown in Fig. 1. All plans underwent QA check by
principal investigator (WRL) and lead physicist (JW).
Radiation delivery
Patients were treated SBRT with 6 to 15 MV beams to a
total dose of 37 Gy to cover at least 95% of the PTV volume
in 5 fractions. Although not based on an external
coordinate system, the term SBRT was used in order to be
consistent with CPT coding. Treatment machine QA was
performed daily and monthly and patient specific QA per-
formed prior to treatment. The dose was selected as an
intermediate between among fractionation schedules pub-
lished at the time of the study design [9–12]. Stereotactic
treatment was accomplished with either implanted tran-
sponders (Calypso) or ExacTrac system and/or cone beam
CT with fiducial markers. 68% of patients were treated
using Calypso transponders. Each of the three institutions
were required to verify that the margins were sufficient
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using the technologies in place at each center be it Calypso,
ExacTrac or CBCT. Treatment was delivered every other
day with a minimum of 36 h to a maximum of 96 h be-
tween consecutive treatments. The total duration of treat-
ment was between 10 and 18 days.
Toxicity and quality of life assessment
Toxicity, as defined by NCI CTCAE v4.0, was assessed
at follow-up visits 1, 3, 6, 12, 18, 24, and 36 months fol-
lowing the end of treatment. Acute toxicity was defined
as occurring within 90 days of completing treatment.
American Urological Association Symptom Scores
(AUASS) [14] and International Index of Erectile Func-
tion (IIEF) [15] scores were collected once prior to treat-
ment and then following treatment at the above time
points via questionnaires. Expanded Prostate Cancer
Index Composite Short Form (EPIC-26) bowel, urinary,
hormonal, and sexual quality of life (QOL) scores [16]
were obtained by questionnaire once prior to treatment
and at 3, 12, 24, and 36 month follow-up appointments.
Statistical methods
The primary endpoint of this phase II study was the in-
cidence of acute and late genitourinary (GU) and
Fig. 1 Representative treatment plan. Isodose curves for a representative 7 field treatment plan in the axial (a), sagittal (b), and coronal (c) planes.
d Dose volume histogram of this plan with PTV in red, rectum in blue, and bladder in yellow
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gastrointestinal (GI) toxicity with the null hypothesis
that SBRT is not tolerable. Secondary endpoints in-
cluded disease-free survival and patient QOL. Estimated
grade 3 rectal toxicity for this regimen was 1.5% based
on a BED3Gy of 78 Gy in 39 fractions. With 60 patients
there would be 77% power to rule out a >7.1% rate of
late Grade 3 toxicity. A rate of ≥ 20% of grade 3 or
greater GU or GI toxicity was considered unacceptable
and 5% acceptable. Interim analyses of the rates of tox-
icity were planned after 15 and 30 analyzable patients
were recruited.
Frequency distributions of patient demographics and
grade 0 to 5 GU and GI toxicity were compared using
Χ2 tests. Actuarial toxicity rates were calculated using
the Kaplan-Meier method. QOL scores were normalized
to baseline value prior to treatment. The Wilcoxon
ranked sign test was used to analyze the change in QOL
scores with time. Median follow-up time was computed
from the end of treatment to the last follow-up date.
Results
Patient demographics
From November 2009 through December of 2013, 60
patients were enrolled. The median age was 66. Median
pre-treatment PSA was 5.8. 11 (18%) patients had T2a
disease, two (3%) had T2b disease, and the remainder
had T1c disease. Twenty- four (40%) patients had a
Gleason score of 6 and 36 (60%) had a Gleason score of
7. Twenty (33%) had low risk disease and 40 (67%) had
intermediate risk disease. The median follow-up time
was 27.6 months (Interquartile range 25–37.0 months).
Patient demographics are summarized in Table 1.
GU toxicity
No grade 3 or greater acute or late GU toxicity was ob-
served (Table 2). Fifteen (25%) patients developed at
least one acute grade 2 GU toxicity with 11 of these pa-
tients having urinary frequency. Five patients reported
grade 2 urinary urgency, three reported grade 2 urinary
retention, and two reported grade 2 urinary tract pain.
Four (6.7%) patients reported one grade 2 late GU tox-
icity (hematuria, urinary incontinence, retention, or ur-
gency). The actuarial rate of late grade 2 or greater
toxicity was 5.0% (95% CI 0–10.5%) at 2 years (Fig. 2a).
GI toxicity
There was one grade 3 late GI toxicity (fecal urgency),
otherwise there was no early or late grade 3 or greater
GI toxicity (Table 2). Three (5%) patients developed
acute grade 2 GI toxicity and 5 (8.3%) patients developed
late grade 2 GI toxicity. The most common GI toxicity
was rectal hemorrhage. The actuarial rate of late grade 2
or greater toxicity was 10% (95% CI 2.4–17.5%) at 2 years
(Fig. 2b).
Quality of life
Quality of life up to 36 months from the completion of
treatment was assessed by the AUASS, IIEF, and EPIC-
26 scores. The median AUASS more than doubled from
4.5 at baseline to 11 (p < 0.01) during treatment, how-
ever the median AUASS of 5 at 36 months post-
treatment approximated the pre-treatment baseline (p =
0.65, Fig. 3a). IIEF scores were significantly worse at 3
(median IIEF score 18, p = 0.03) and 36 months (median
IIEF score 17, p = 0.01) post-treatment compared to the
pre-treatment baseline however the median score only
decreased by 2 from 19 to 17 over this time (Fig. 3b).
Consistent with the results of the AUASS, EPIC-26
scores in the urinary domain were significantly de-
creased from a median baseline of 94.4 pre-treatment to
91.7 at 3 months (p < 0.01) and 88.9 at 12 months (p <
0.04) following treatment but returned to baseline at
later timepoints (median score of 96.3 at 36 months, p =
0.65, Fig. 4a). Median EPIC-26 scores in the sexual do-
main were significantly decreased at 24 (57.1, p < 0.01)
and 36 (54.2, p = 0.02) months post-treatment compared
to a pre-treatment median of 67.8 although the number
of responses returned at these timepoints were low
(Fig. 4b). There was no significant decrease in the
36 month follow-up median EPIC-26 scores in either the
bowel (p = 0.22) or hormonal (p = 0.53) domains.
(Fig. 4c-d).
Discussion
In this report of a phase II multi-institutional study of
SBRT for low to intermediate risk prostate cancer low
Table 1 Baseline characteristics of patients
Characteristic





Native American 1 (1.7)





Number of Biopsy Cores, Median (Range) 12 (2–26)
Number of Positive Cores, Median (Range) 3 (1–10)
Gleason Score, Number (Percentage)
6 24 (40)
7 36 (60)
Median Follow-Up, Months 27.6
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rates of genitourinary and gastrointestinal toxicity were
observed with little change in QOL by AUASS as well as
IIEF and EPIC-26 scores.
Clinical data [5, 6] suggest that hypofractionated radiation
for prostate cancer may improve the therapeutic ratio for
this disease. This data has prompted three non-inferiority
studies in the last decade investigating treatment in 19 to
28 fractions compared to 39 or more [17–19]. Two of these
studies have recently demonstrated hypofractionated treat-
ment to be non-inferior to conventional fractionation with
Table 2 Crude toxicity rates
Genitourinary Toxicity Gastrointestinal Toxicity
Acute Late Acute Late
Grade Number (%) Grade Number (%) Grade Number (%) Grade Number (%)
1 44 (73.3) 1 22 (36.7) 1 19 (31.7) 1 15 (25.0)
2 15 (25.0) 2 4 (6.7) 2 3 (5.0) 2 5 (8.3)
3 0 (0) 3 0 (0) 3 0 (0) 3 1 (1.7)
4 0 (0) 4 0 (0) 4 0 (0) 4 0 (0)
5 0 (0) 5 0 (0) 5 0 (0) 5 0 (0)
Rates of early, occurring < 90 days from the end of treatment, and late, occurring >90 days from the end of treatment, toxicity
Fig. 2 Actuarial rates of toxicity. Actuarial rates of grade 2 or greater late genitourinary (a) and gastrointestinal (b) toxicity
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the best estimate hazard ratios for disease free survival fa-
voring hypofractionation [18, 19].
At the same time encouraging results with SBRT for
sites outside of the prostate have generated enthusiasm
in extending this technique to prostate cancer patients.
To this end a number of other phase I and/or II trials
have been initiated to demonstrate the feasibility and
tolerability of SBRT for prostate cancer.
The observed toxicity of these trials is summarized in
Table 3. Consistent with these prior findings, of the 60
Fig. 3 Patient reported QOL scores following treatment. AUASS (a) and IIEF (b) scores at baseline, on treatment, and 3, 6, 12, 18, 24, and
36 months post-treatment. The number of responses obtained at each time point is indicated
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Fig. 4 Prostate cancer treatment specific QOL scores following treatment. EPIC-26 scores in the urinary (a), sexual (b), bowel (c), and hormonal (d)
domains at baseline and 3, 12, 24, and 36 months post-treatment. The number of responses obtained at each time point is indicated
Table 3 Previously published rates of toxicity following prostate SBRT
Study n Dose/
Fractions
Timepoint Genitourinary Toxicity Gastrointestinal Toxicity
Grade 2 ≥ Grade 3 Grade 2 ≥ Grade 3
Madsen [10] 40 33.5/5 Within or after 1 month Acute 20.5% Acute 2.5% Acute 13% Acute 0%
Late 20% Late 0% Late 7.5% Late %
Tang [12] 30 35/5 ≤6 months 13% 0% 7% 0%
King [9] 41 36.25/5 ≥6 months 24% 5% 15% 0%
McBride [11] 34 37.5–36.25/5 Within or after 3 months Acute 19% Acute 0% Acute 7% Acute 0%
Late 17% Late 2% Late 7% Late 5%
Hannan [8] 91 45–50/5 Within or after 9 months Acute 22% Acute 0% Acute 20.9% Acute 2.2%
Late 20.9% Late 5.5% Late 13.2% Late 6.6%
Alonghi [7] 40 35/5 Within or after 6 months Acute 40% Acute 0% Acute 10% Acute 0%
Late 2.5% Late 0% Late 0% Late 0%
Reported toxicity of previously published phase I and/or II trials of SBRT for prostate cancer; n = number of patients on trial, dose is reported in Gy
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patients enrolled on this study only one case of grade 3
gastrointestinal toxicity was observed and no grade 3 or
greater genitourinary toxicity was reported. It is possible
however that late GU side effects may be underestimated
due to the lack of identification of the intraprostatic ur-
ethra by imaging or introduction fo a Foley catheter at
the time of simulation. There were very similar rates of
acute grade 2 GU and GI toxicity (25 and 5%, respect-
ively) in this study as seen in RTOG 04-15 with either
hypofractionated (24.7 and 9.7%, respectively) or con-
ventionally fractionated (23.7 and 9.9%, respectively)
treatment [18]. Late grade 3 or greater toxicity was rare
in this study (1 case of grade 3 GI toxicity) as well as
other trials of SBRT (Table 3) or RTOG 04-15 where all
rates were 6.6% or less [7–12, 18]. A preliminary report
of a randomized phase II trial, RTOG 0938, comparing
SBRT in 36.25 Gy in 5 fractions to hypofractionated
treatment to 51.6 Gy in 12 fractions for favorable risk
prostate cancer showed similar low rates of late grade 3
or greater GI or GU toxicity with SBRT (0.8%) or hypo-
fractionated (1.7%) treatment [20].
Similar to the limited toxicity in this study, follow-up
extending out to 36 months post-treatment showed lim-
ited to no change in QOL as measured by either
AUASS, IIEF scores, or EPIC-26 scores in either the
urinary, bowel, sexual, or hormonal domains. There was
a significant decline within the bowel domain of the
EPIC-26 scores perhaps in concert with the slight in-
crease in late, as compared to early, grade 2 or grade
gastrointestinal. Similar increases in late bowel toxicity
have been seen in phase III dose escalation studies of
conventionally fractionated radiation and hypofractio-
nated versus conventionally fractionated treatment.
These results should be interpreted with caution how-
ever given the relatively low rate of events in this study
and decline in responses to the QOL questionnaires
such that less than a third of patients responded to the
EPIC-26 questionnaire at 36 months.
It is tempting to comment on the disease status of
these patients, however with a short median follow-up
of 27.6 months, the ability to make inference on the effi-
cacy of SBRT is limited. Longer follow-up is required for
a more robust outcome analysis. If disease control is
found to be similar with the observed low rates of tox-
icity, the option of decreasing treatment time for men
with low to intermediate risk prostate cancer will have
significant implications for patient convenience and cost.
This study only included men with low to intermediate
risk disease and the PSA in those with a Gleason score
of 7 was limited to 10 or less. Therefore the results of
this study should not be extended to patients with
higher risk disease who might require coverage of the
seminal vesicles in the treatment volume or those pa-
tients treated with concurrent androgen deprivation
therapy, both of which were not allowed on this study.
In addition it is likely that for at least some men on this
study there is little to no advantage to having undergone
radiation as compared to active surveillance. The present
results should therefore have limited impact on the deci-
sion to undergo treatment or not.
Conclusions
In summary for men with low to intermediate risk prostate
cancer toxicity following SBRT is low and similar to con-
ventionally fractionated and hypofractionated treatment
with limited to no change in QOL. Further follow-up is
warranted to address disease control after this treatment.
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